ライフサイエンスコーパス: drug

1 entration than equivalent quantities of free drug.

2 sis isolates as susceptible/resistant to the drug.

3 gistered to the trial for a sequential trial drug.

4 ents who received at least one dose of study drug.

5 pulations of patients who could tolerate the drug.

6 ected with fungi that are susceptible to the drug.

7 pressant and by the public as a recreational drug.

8 to 7 after the repeated daily dosing of the drug.

9 or the finding of a usable h-P2X7 antagonist drug.

10 (35.6%) of whom were still prescribed these drugs.

11 future efforts in the development of anti-TB drugs.

12 n be partially reversed by immunosuppressive drugs.

13 macokinetics of first-line anti-tuberculosis drugs.

14 of users of any other oral glucose lowering drugs.

15 t for affinity-guided delivery of anticancer drugs.

16 o enhance the activity of current antifungal drugs.

17 -five patients required 1 IMT and 4 needed 2 drugs.

18 e to ionizing radiation and chemotherapeutic drugs.

19 gn of live attenuated vaccines and antiviral drugs.

20 es represent potential targets of antifungal drugs.

21 ity-based probes and as irreversibly binding drugs.

22 at common targets (TE) activated by the same drug (5-azacytidine) elicit an immune response, which ma

23 viral, antibacterial, anticancer and cardiac drugs(6,7).

24 e: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 9

25 prophylaxis to monitoring of antiarrhythmic drug (AAD) therapy.

26 Importantly, we identified two FDA-approved drugs able to ameliorate these phenotypes.

27 release and measure the antibody-conjugated drug (acDrug) concentration.

28 cologically diverse and clinically essential drugs act through overlapping and distinct mechanisms to

29 reuptake inhibitors (SSRIs), initiate their drug actions by rapid elevation of serotonin, but they t

30 o calcium imaging revealed that different GA drugs activate a shared ensemble of CeA(GA) neurons.

31 We identify an ATS pertaining to which drug add-ons to recommend when metformin in monotherapy

32 e significantly improved, compared to parent drug administered orally.

33 EDLINE, and publicly available U.S. Food and Drug Administration (FDA) drug reviews, all reported CVD

34 lar assays for SARS-CoV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization (E

35 en developed and approved by the US Food and Drug Administration (FDA) for human use.

36 0.5 ng/mL as recommended by the US Food and Drug Administration (FDA).

37 Elimination Centre started programmatic mass drug administration (pMDA) campaigns with dihydroartemis

38 ate the effectiveness of reactive focal mass drug administration (rfMDA) and reactive focal vector co

39 y that will likely pave the way for Food and Drug Administration approval in the United States.

40 ropean Medicines Agency or the U.S. Food and Drug Administration for the management of moderate to se

41 that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression.

42 approved by the FDA (United States Food and Drug Administration) is the prostate specific antigen (P

43 ical device regulatory agencies, US Food and Drug Administration, as well as payers, that we believe

44 To date, there is no Food and Drug Administration-approved targeted therapy for advanc

45 ifts in the magnitude of anorexia (e.g., via drugs) affect disease dynamics and virulence evolution.

46 acy in clinical isolates for quinolones from drug affinity (R2>0.9).

47 Pharmacokinetic studies of released drugs after intravenous administration showed that the l

48 he potential of solenopsins as novel natural drugs against neglected parasitic diseases caused by kin

49 may aid in the development of more specific drugs against this target.

50 Copper-chelating drugs also significantly increased the number of tumor-i

51 e sensitive to other p53-dependent cytotoxic drugs, also display increased sensitivity to XL177A.

52 that individual differences in responses to drug and nondrug reward are linked and together form a r

53 ion to Diels-Alder (DA) adducts of furylated drugs and acetylenedicarboxylate derivatives, initiating

54 hematopoietic cells, then immunosuppressive drugs and antimicrobial approaches to infection control.

55 implications for optimising antitrypanosomal drugs and averting cross-resistance.

56 Some antiviral drugs and broadly reactive influenza vaccines that targe

57 ce companies to generate comparative data on drugs and devices and assure timely availability of evid

58 ncer cell lines that are resistant to cancer drugs and diminished ERK signaling.

59 Of approximately 4000 generic drugs and drug classes evaluated, the method detected 19

60 ist in target identification of antimalarial drugs and highlight the potential to selectively target

61 xtraction (SPME) method capable of analyzing drugs and metabolic products in biofluids and living tis

62 rm rescue by low temperature, CFTR-targeting drugs and second-site revertant mutation R1070W.

63 jects is an important measure of efficacy of drugs and vaccines.

64 Database in 2000-2013, employing diagnoses, drugs, and procedure codes to define diseases and proced

65 ibe a platform for the detection of IgG anti-drug antibodies that may provide an initial screen for a

66 Pharmaceutical drugs are an important part of the global healthcare sys

67 sponses elicited by two unrelated individual drugs are correlated.

68 toxicity evaluations of nanotechnology-based drugs are essential to support initiation of clinical tr

69 at the prescriptions top-ranked repositioned drugs are significantly associated with lower odds of AD

70 d as prescription of blood pressure-lowering drugs as obtained from the national drug registry.

71 s, attesting the ability of the platform for drug assays employing cyclic drug exposure regimens.

72 e by drug-paired cues.SIGNIFICANCE STATEMENT Drug-associated cues precipitate relapse, which is corre

73 mostly symptomatic, centred on decongestive drugs, at best tailored according to the initial haemody

74 sitizing glioblastoma cells to TMZ and other drugs available in the market.

75 iT, we found that the anti-tuberculosis (TB) drug bedaquiline (BDQ) is localised not only in foamy ma

76 Advances in our understanding of drug block and inactivation mechanisms are noted, but a

77 ades and unveiled a novel role of anticancer drugs bortezomib and carfilzomib in their regulation of

78 the downstream release of the small molecule drug by a retro DA reaction.

79 peutic target of anticancer and anti-obesity drugs by inhibiting its DNA-binding activities.

80 his work, we designed a new chemotherapeutic drug candidate against cancer, namely, [Ru(DIP)(2)(sq)](

81 but also guides the design and selection of drug candidate molecules.

82 mpounds into high-quality chemical probes or drug candidates is an ongoing challenge in biomedical re

83 of compounds, with some ending as promising drug candidates.

84 Of approximately 4000 generic drugs and drug classes evaluated, the method detected 19 distinct

85 dely used in pharmaceutical industry such as drug coatings due to their low cost, processability and

86 ombo predictions closely agree with measured drug combination efficacies both in vitro (Pearson's cor

87 n four diseases show that network-principled drug combinations tend to have low toxicity.

88 inflammatory liver disease caused by several drugs commonly used in clinical practice, herbs and diet

89 nder the curve accumulation, time of maximum drug concentration, and in situ partition ratios.

90 orter assay can be used for an estimation of drug concentrations.

91 Antibody-Drug Conjugates (ADCs) developed as a targeted treatment

92 astuzumab, used for antibody engineering and drug conjugation.

93 Incidences of adverse events, drug continuation, implantable cardioverter defibrillato

94 to simplified payment administration, lower drug costs, and other factors.

95 ata Collection on Adverse Events of Anti-HIV Drugs (DAD) study has reported an increased risk of card

96 involved in drug resistance (drug extrusion, drug degradation, and DNA damage repair) and using rate

97 The efficiency of drug delivery and sensory perception is intertwined with

98 lobal health and developed world long-acting drug delivery applications.

99 These novel formulations will address drug delivery challenges and have great potential to imp

100 hanced tissue distribution and intracellular drug delivery of molecules, nanoparticles, and other the

101 goal of this study was to characterize FUSIN drug delivery outcome in mice with regard to its depende

102 on, particularly nerve guidance conduits and drug delivery strategies.

103 st and smart "all-in-one" nanoparticle-based drug delivery system capable of overcoming biological ba

104 In this study, electrospun membrane drug delivery systems consisting of the antibiotic cipro

105 ecent advances for the development of ocular drug delivery systems.

106 Drug delivery to the brain always remains a challenging

107 Besides sustained drug delivery, AFL-assisted powder reservoir patch deliv

108 The applicability of this approach for drug delivery, bioimaging, and cell targeting was also d

109 y extends the capabilities in targeted cargo/drug delivery, environmental remediation, and other pote

110 ed immune modulation and macrophage-mediated drug delivery, which will further enhance current tumor

111 widely considered as an optimal material for drug delivery.

112 icking of TM ions in biological systems, and drug design in metalloprotein platforms.

113 A drug design strategy is here reported, which took SAC an

114 emonstrates the potential of structure-based drug design to develop more subtype-selective GPCR ligan

115 s for studies with venom compounds, PIs, and drug design.

116 For effective integration into drug development and clinical practice, robust assays wi

117 plications for anti-Alzheimer's research and drug development and the broader field of tauopathies in

118 ing lays the groundwork to streamline future drug development efforts.

119 t applications across disease prediction and drug development in relation to the COVID-19 pandemic ar

120 ng may lead to new targets or approaches for drug development or treatment regimens that may affect b

121 Novel drug development, testing and progression to clinical tr

122 lity of mitophagy pathways and prospects for drug discovery and consider intervention points for mito

123 allenges the current paradigm of traditional drug discovery and development, which usually takes year

124 For decades, traditional drug discovery has used natural product and synthetic ch

125 ar and an excellent platform for preclinical drug discovery studies.

126 e related research, particularly involved in drug discovery targeting metalloenzymes.

127 t of improved mixture-based, high-throughput drug discovery techniques.

128 od was successfully used in several 'inverse drug discovery' programs that use high-throughput techni

129 ening assays, used routinely in antimalarial drug discovery, against the whole organism.

130 ntists and educators working in the areas of drug discovery, vaccine design, and biomedical and biote

131 e present and future value of simulation for drug discovery, we review key applications of advanced m

132 hesis technologies to enable next-generation drug discovery.

133 ceptors in recombinant systems has precluded drug discovery.

134 assays in the early ADME profiling space in drug discovery.

135 uch as structural biology, cell imaging, and drug discovery.

136 ric cancer, and is an important biomarker in drug discovery.

137 t would bypass the time-consuming and costly drug-discovery process.

138 stered treatments, number of IAC injections, drug dose, mean injection time, injection method (pulsat

139 zed HLCs can be used for pharmacokinetic and drug-drug interaction studies.

140 seizures has changed minimally despite poor drug efficacy.

141 fter percutaneous coronary intervention with drug-eluting stents, whereas extended-term DAPT reduces

142 Improving drug entry into the testes with drugs that use endogenou

143 schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for them.

144 Slower plasma clearance and increased drug exposure over time of ALDC1 were observed compared

145 he platform for drug assays employing cyclic drug exposure regimens.

146 s evaluated, the method detected 19 distinct drug exposures with statistically significant, large rel

147 ms of reactions involved in drug resistance (drug extrusion, drug degradation, and DNA damage repair)

148 From the Drugs@FDA, clinicaltrials.gov, MEDLINE, and publicly ava

149 ice-weekly intravenous administration of the drug for three weeks (p < 0.0001, and p = 0.001 for saci

150 The optimal concentration of both drugs for BAT was determined as 5 mg/mL.

151 should facilitate the discovery of antiviral drugs for this important zoonotic pathogen.

152 trials supporting FDA approval of anticancer drugs from 1998 to 2018 were evaluated.

153 f TRPM7 channel activity by the FDA-approved drug FTY720 increased the sensitivity of T cells to the

154 s that could be rescued by the tic-relieving drug haloperidol.

155 zinamidase, however, the exact target of the drug has been difficult to determine.

156 r, small-molecule orally available antiviral drugs have yet to be developed.

157 BL) antibiotics are the most common cause of drug hypersensitivity.

158 st one fully active, approved antiretroviral drug in at least one but no more than two antiretroviral

159 ants who received at least one dose of study drug in terms of treatment-emergent adverse events.

160 r values revealed patient subgroups for each drug in which inter-patient variability was largely decr

161 nce of albuminuria amongst people who inject drugs in London and to test any potential associations w

162 dine calcium channel blockers are reasonable drugs in patients with normal ventricular systolic funct

163 In this analysis of branded drugs in the US from 2007 to 2018, mean increases in lis

164 auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse model and establish an adequate dos

165 FDA-approved oncology and natural substance drugs included in two NCI drug libraries representing a

166 We will discuss the modes of action by those drugs including inducing innate sensing and limiting imm

167 MRGPRX2 responds to various drugs, including opioids, to elicit pseudoallergic react

168 Drug induced liver injury (DILI) is a necro-inflammatory

169 e over the past several years in elucidating drug-induced changes at molecular, cellular, and physiol

170 with which to assess detailed mechanisms of drug-induced effects on cardiac muscle contractility.

171 Drug-induced hypersensitivity syndrome/drug reaction wit

172 e-dependent individuals are a consequence of drug-induced neural adaptations.

173 1alpha and IGFBPs predict a poor response to drugs inducing unresolvable UPR and possibly other forms

174 ality were: P: age, gender and ACLF type; I: drug, infection, surgery, and variceal bleeding; R: syst

175 elopment of automatic systems for control of drug infusion in anaesthesiology.

176 lymphomas on MNT for survival suggests that drugs inhibiting MNT could significantly boost therapy o

177 activation, either through receptor-specific drug intake, genetically predisposed irregular 5-HT rece

178 Oral delivery of protein drugs is considered a life-changing solution for patient

179 r (CRPC) as the oral administration of these drugs is largely hampered by their low and highly variab

180 NPC1-SSD or the addition of the anti-fungal drug itraconazole abolishes NPC1 activity in cells.

181 The drug JQ1, which inhibits histone acetyl-lysine reader br

182 we profiled resistance to the anti-influenza drug laninamivir in AIVs with substitutions known to imp

183 natural substance drugs included in two NCI drug libraries representing a variety of chemical struct

184 hrine are profoundly altered by recreational drugs like ethanol, but the consequences of these change

185 machine is required to design high-quality, drug-like molecules within the appropriate chemical spac

186 s a potent, selective inhibitor of SHP2 with drug-like properties, and targeting SHP2 may serve as a

187 -10 kDa) size, stability, and versatility in drug-like roles.

188 on microscopy, encapsulation efficiency, and drug loading capacity.

189 owever, current approaches show insufficient drug-loading capacity and inefficient drug release, and

190 The prescription drug market in the United States relies on competition t

191 tably impairs phagocytosis, and increases TB drug metabolism.

192 AhR sensing of TB drugs modulates host defense mechanisms, notably impairs

193 therapeutic areas, providing differentiated drug molecules with increased specificity and extended h

194 ge functionalization of natural products and drug molecules, stereospecific synthesis of useful alpha

195 e most common therapeutic needs involved new drugs (n = 149, 51.0%), cell regeneration (n = 115, 39.4

196 of this colonic intestinalization process by drugs, nutrients, and pre- or probiotics might offer bet

197 an monitor the effect of an immunomodulatory drug on brain-infiltrating leukocytes.

198 New drugs or combinations are needed to improve patient ther

199 alth, particularly in Southeast Asia, and no drugs or vaccines are available.

200 eneration compared with those not taking the drug (OR 0.70, 95%CI 0.55-0.88).

201 Single-drug oral selinexor induced durable responses and had a

202 ignificantly increased the time spent in the drug-paired chamber compared to the saline-paired chambe

203 D1-MSNs induced during reinstated cocaine by drug-paired cues.SIGNIFICANCE STATEMENT Drug-associated

204 cy by prolonging the release of nucleic acid drug payload for sustained, long-term gene expression or

205 provide an overview of oligonucleotide-based drug platforms, focusing on key approaches - including c

206 graphic characteristics, past diagnoses, and drug preparation and administration practices.

207 loop involving the autocrine remodeling of a drug-protective ECM.

208 l Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opio

209 us (HIV) infections among persons who inject drugs (PWID).

210 s of clinicians on the spectrum of cutaneous drug reaction related to entecavir therapy.

211 Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (D

212 who received at least one dose of any study drug, regardless of whether it was their randomly assign

213 lowering drugs as obtained from the national drug registry.

214 m)Tc-PHC-102 was well tolerated and no study drug-related adverse events were recorded.

215 actam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths)

216 atients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxic

217 icient drug-loading capacity and inefficient drug release, and require complex modification processes

218 of the durable responses initiated by these drugs remain unknown.

219 Drug repurposing is potentially the fastest available op

220 Overall, this systematic approach to drug repurposing lays the groundwork to streamline futur

221 Drug repurposing signifies an appealing approach to enha

222 data in the downstream applications such as drug repurposing, disease modeling and gene function pre

223 The homopolymer designs have a drug reservoir potential of well over a year at mg/day d

224 th known mechanisms of reactions involved in drug resistance (drug extrusion, drug degradation, and D

225 trimoxazole, and chloramphenicol), extensive drug resistance (XDR) (MDR plus non-susceptible to fluor

226 generalizable activation site that mediates drug resistance and confirm its impact in BRAF, EGFR, HE

227 The emergence of drug resistance in Helicobacter pylori has resulted in a

228 HIV drug resistance is a major threat to achieving long-term

229 iciency and substrate specificity leading to drug resistance is unclear.

230 enetic modifications are closely involved in drug resistance of tumor cells.

231 Dried blood spots (DBS)-based drug resistance testing, widely studied for HIV-1, has n

232 Cancer, a disease that is prone to drug resistance, is in principle susceptible to such tra

233 splatin, whereas its overexpression promotes drug resistance.

234 ddress the multitude of challenges in cancer drug resistance.

235 mechanisms involved in stress tolerance and drug resistance.

236 such as treatment response and emergence of drug resistance: inference based on genomic, transcripto

237 multiplexed identification of dozens of HIV drug-resistance mutations.

238 biotic of last resort used in treating multi-drug resistant bacterial infections in humans.

239 iotics against two clinically isolated multi-drug-resistant bacteria strains (including carbapenem-re

240 The emergence of multi-drug-resistant bacterial strains further complicates pat

241 -LC-07-48 which exhibited greater potency in drug-resistant NSCLC cells (IC(50) = 17 nM) and in mice

242 in ensuring that all persons diagnosed with drug-resistant TB are started on an appropriate treatmen

243 ding infectious cause of death globally, and drug-resistant TB strains pose a serious threat to contr

244 found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive.

245 d suggest a mechanism for the development of drug-resistant tumors and a target for overcoming resist

246 st various malignant solid tumors, including drug-resistant tumors and metastatic tumors.

247 ing Initiative study, and the analyses of 64 drug responses, we demonstrate that MKpLMM consistently

248 able U.S. Food and Drug Administration (FDA) drug reviews, all reported CVD events across latter-phas

249 tuent of cannabis and is responsible for the drug's reinforcing effects.

250 patible with late-stage functionalization of drug scaffolds and natural products.

251 Using RNA sequencing and drug screening, we find that treatment of FLT3 internal

252 cardiac disease and serve as a test bed for drug screening.

253 that propensity to discount cost imposed on drug seeking is associated with dependence severity.

254 e conceptual distinctions between compulsive drug-seeking behaviour and compulsive drug-taking behavi

255 stant TB (MDR-TB) emerging (8%), compared to drug-sensitive TB (0.3%).

256 y for 7 days (inhA group), and controls with drug-sensitive TB received standard dose (5 mg/kg/day).

257 uilt gene expression-based models to predict drug sensitivity for 265 common anticancer compounds.

258 etastable bioanalyte toward predicting tumor drug sensitivity.

259 ectable in brain tissue) and found that this drug still powerfully attenuates heroin-induced brain ox

260 n known amounts of HCPs to purified antibody drug substance with low levels of HCPs, we demonstrated

261 If the annual number of isolates tested for drug susceptibility is doubled, this strategy could incr

262 Despite the WHO's call for universal drug susceptibility testing for all patients being evalu

263 f this transcriptional cascade suggests that drug synergy may ensue when the transcriptional response

264 ulsive drug-seeking behaviour and compulsive drug-taking behaviour (that is, use).

265 an SKI complex as a broad-spectrum antiviral drug target and identifies lead compounds for further de

266 e-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecu

267 osynthesis of epinephrine and is a potential drug target, primarily for the control of hypertension.

268 transporter, PfFNT, as a novel antimalarial drug target.

269 Our drug-target analysis shows 1/3 of patients with germline

270 fined test cases, our work demonstrates that drug-target binding is a major predictor of bacterial re

271 volves many additional effects downstream of drug-target binding.

272 and holds great potential to identify novel drug targets and vaccine development.

273 ee amino acids from human hemoglobin and are drug targets for the design of novel antimalarial agents

274 Pyrazinamide is a pro-drug that is converted into pyrazinoic acid (POA) by pyr

275 in the race to identify safe and efficacious drugs that can be used to prevent and/or treat COVID-19.

276 e briefly update the current small molecular drugs that could synergize with immunotherapy, especiall

277 should be taken into account when developing drugs that modulate BAX activity.

278 d by modulation of the circadian system with drugs that target the clock, and that a dysfunctional cl

279 Improving drug entry into the testes with drugs that use endogenous transport pathways may lead to

280 uction of intracellular levels of anticancer drugs through ATP-binding cassette (ABC) pumps.

281 antified the flow and flux of small molecule drugs through the layers and structures of ex vivo nude

282 primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure im

283 ng gene therapy and repurposing an available drug to effectively treat both oral cancer metastasis an

284 D2R) levels and the failure of antipsychotic drugs to rescue adult behavioral defects.

285 egies for selectively imaging and delivering drugs to tumours typically leverage differentially upreg

286 Herein, an antirheumatic targeted drug tocilizumab (TCZ) is conjugated to polymer nanopart

287 expression noise is important for improving drug treatment and the performance of synthetic biologic

288 itors, thereby promoting cell survival after drug treatment.

289 developmental models, genetic perturbations, drug treatments, and disease states.

290 primary outcomes for phase II and phase III drug trials reported to the ClinicalTrials.gov registry.

291 esign may be useful for other GA repurposing drug trials.

292 ndent predictors of infection were injection drug use as a risk factor for HIV acquisition (aOR, 2.2;

293 linked and together form a risk profile for drug use or abuse, particularly in young adults.

294 k of HIV and sequelae of injection and other drug use, and they have a continuing role in addressing

295 ment of safety and tolerability of the study drugs was done in all patients randomly assigned to trea

296 ol group of patients exposed to linezolid, a drug with similar indications.

297 Drugs with anti-inflammatory and anti-fibrotic effects a

298 he published mechanisms for three classes of drugs with different mechanisms of action.

299 arned a great deal about how these 'miracle' drugs work.

300 Such a drug would raise the hope for a cure to many P2X7-depend